The selection of CRL as a partner for the GLP toxicology study of TOL2 follows an in-depth assessment of external opportunities conducted by Toleranzia during the fall. CRL is a well-established global contract research organization with high-quality operations and significant expertise and experience in regulatory toxicological studies related to immune-modulating drug candidates. The GLP toxicology study results will form an essential part of Toleranzia’s clinical trial application for the upcoming clinical study in patients with myasthenia gravis, an autoimmune nerve and muscle disease that often leads to severe muscle weakness and a difficult life situation.
 
“We are pleased to announce the selection of Charles River Laboratories as our partner for the GLP toxicology study of TOL2, a drug candidate with potential to revolutionize the treatment of myasthenia gravis. CRL has all the necessary technical, scientific, and quality systems needed for this important step in documenting the safety profile of TOL2 ahead of future clinical studies,” comments Charlotte Fribert, CEO of Toleranzia.
 
 
For further information, please contact:
Charlotte Fribert - CEO, Toleranzia AB
Tel: +46 763 19 98 98
Email: charlotte.fribert@toleranzia.com
 
About Toleranzia AB (publ)
Toleranzia AB (publ) develops drugs that harness the power of the immune system for the treatment of autoimmune orphan diseases. The drugs, which target the cause of the disease, can cure or significantly alleviate the disease and not, like current treatments, merely reduce the symptoms. They have the potential to be the first long-acting or curative therapies that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. Toleranzia's shares are listed on the Nasdaq First North Growth Market and Mangold Fondkommission AB, 08-503 015 50, CA@mangold.se, is the company's Certified Adviser.